Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural Killer Group 2 Member D (NKG2D)
- Target
- NKG2D
- Molecular classification
- Receptor, C-type lectin-like receptor, Type II transmembrane protein
01
Overview
The Natural Killer Group 2 Member D (NKG2D) receptor is an activating receptor expressed on NK cells and some T cells. It recognizes stress-induced ligands on target cells, triggering cytotoxicity and cytokine secretion. NKG2D plays a crucial role in immunosurveillance and is targeted by bispecific antibodies in cancer immunotherapy.
02
Mechanism of action
Recruits and activates NK cells and other cytotoxic lymphocytes to tumor sites, enhances antibody-dependent cell-mediated cytotoxicity (ADCC)
03
Biological functions
Immune responseNK cell activationT cell co-stimulationCytotoxicityCytokine secretionImmune surveillance
04
Disease associations
CancerInfectionAutoimmune diseaseTransplantation rejection
05
Safety considerations
Potential for off-target effectsCytokine release syndromeTumor evasion through ligand shedding or downregulation
06
Interacting drugs
Bispecific antibodies targeting NKG2D and tumor antigens
07
Biomarkers
MICAMICBULBP1ULBP2ULBP3ULBP4ULBP5ULBP6Rae-1 familyH60MULT-1
Beyond the preview
Go deeper on Natural Killer Group 2 Member D (NKG2D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Natural Killer Group 2 Member D (NKG2D).